Top 7 Nanomedicine startups in USA
Mar 25, 2026
|
Like
24
1
Funding: $135.5M
The Cour particle platforms provide a novel and highly specific immune targeting capability which may be safely applied to severe inflammatory modulation, and immune (antigen) tolerization.
The Cour particle platforms provide a novel and highly specific immune targeting capability which may be safely applied to severe inflammatory modulation, and immune (antigen) tolerization.
2
Funding: $100M
Addition Therapeutics (University of California spinoff) develops RNA-only therapeutics using PRINT technology for genetic medicine. PRINT stands for Precise RNA-Mediated Insertion of Transgenes and involves the creation of all-RNA, non-viral lipid nanoparticles. In drugs created using PRINT technology, only the genetic sequence of the messenger RNA is altered, all other components remain unchanged. The company claims this enables the creation of safer, long-lasting, single-dose treatments that overcome the limitations of existing genetic medicine. One of the company's primary goals is the treatment of HIV. With a grant from the Gates Foundation, Addition is developing PRINT therapy to stimulate endogenous antibody production with a single dose for "lifelong protection against HIV."
Addition Therapeutics (University of California spinoff) develops RNA-only therapeutics using PRINT technology for genetic medicine. PRINT stands for Precise RNA-Mediated Insertion of Transgenes and involves the creation of all-RNA, non-viral lipid nanoparticles. In drugs created using PRINT technology, only the genetic sequence of the messenger RNA is altered, all other components remain unchanged. The company claims this enables the creation of safer, long-lasting, single-dose treatments that overcome the limitations of existing genetic medicine. One of the company's primary goals is the treatment of HIV. With a grant from the Gates Foundation, Addition is developing PRINT therapy to stimulate endogenous antibody production with a single dose for "lifelong protection against HIV."
3
Funding: $13.5M
Zylö Therapeutics has an innovative sustained-release drug-delivery system that uses patented hydrogel-derived nanoparticles
Zylö Therapeutics has an innovative sustained-release drug-delivery system that uses patented hydrogel-derived nanoparticles
4
Funding: $2.4M
Nanomedical Diagnostics is the first company to combine expertise in biology, nanotechnology, surface chemistry, engineering, and manufacturing to create practical and scaleable graphene biological field effect transistor (BioFET) products. Our ongoing mission is applying our cutting-edge capabilities to produce affordable diagnostic and monitoring platforms that deliver accurate, timely health information and improve patient outcomes and lives.
Nanomedical Diagnostics is the first company to combine expertise in biology, nanotechnology, surface chemistry, engineering, and manufacturing to create practical and scaleable graphene biological field effect transistor (BioFET) products. Our ongoing mission is applying our cutting-edge capabilities to produce affordable diagnostic and monitoring platforms that deliver accurate, timely health information and improve patient outcomes and lives.
5
Funding: $4.6M
Helex is revolutionizing genomic medicine and advances in treating genetic kidney diseases. It designed lipid nanoparticle technology for targeted drug delivery and an intelligent drug design platform that enables de-risked, scalable and affordable therapeutics. Therapeutic payloads are directed to specific organs and cells beyond the liver filter. The technology is said to minimize immune response and eliminate the risk of insertional mutagenesis linked with viral vectors. Also it has greater scalability than viral vectors due to their simpler production process.
Helex is revolutionizing genomic medicine and advances in treating genetic kidney diseases. It designed lipid nanoparticle technology for targeted drug delivery and an intelligent drug design platform that enables de-risked, scalable and affordable therapeutics. Therapeutic payloads are directed to specific organs and cells beyond the liver filter. The technology is said to minimize immune response and eliminate the risk of insertional mutagenesis linked with viral vectors. Also it has greater scalability than viral vectors due to their simpler production process.
6
NuVascular Technologies, Inc. is developing the next-generation of medical devices that will specifically treat patients suffering from end-stage renal (kidney) disease with the goal of helping patients live better and longer lives.
7
Illuminate Therapeutics is a spin-off of Pennsylvania State University developing an effective and targeted treatment for head and neck cancer that will cause minimal damage to surrounding healthy tissue. The potential treatment utilizes Illuminate's drug delivery and release platform based on light-activated nanoparticles (LADDR). It uses very focused laser to activate a light sensitive nanoparticle that delivers a nucleic acid that would target many different genes within the cancer cell. Such a precise methodology enables to use more potent chemicals to target the cancer cell.
★
See also:
